Table 2.
No. of patients | 47 |
---|---|
Age, yearsa | 66.1 (41–79) |
Race | |
Caucasian | 43 |
African American | 3 |
Asian | 1 |
Gleason at diagnosisa | 7.9 (6–10) |
Baseline PSAa | 252 (5–1068) |
Trial armb | |
Docetaxel | 14 |
Docetaxel and thalidomide | 33 |
Response | |
Docetaxel | 7 (50%) |
Docetaxel and thalidomide | 24 (73%) |
Data are expressed as the median value and range.
The original trial consisted of 25 patients receiving monotherapy, and 49 patients receiving the combination. There were 9/24 (37.5%) responses for the single agent, and 25/47 (53%) responses for the combination.25 We included the maximum number of patients from the original trail who had a sufficiently large DNA sample for analysis with DMET.
Characteristics of the 47 patients in this pharmacogenetic study. The parent study enrolled 75 patients in a 2:1 randomization between the two arms. Response rates using the prostate-specific antigen (PSA) Working Group consensus criteria were slightly higher in the subset of patients included in this study when compared with the patients in the parent study.